Sun Pharma introduces Riomet ERSun Pharma’s Riomet ER is the first and only liquid formulation of metformin for Type 2 diabetes patients. Seqirus gets FDA nod for FluadSeqirus' Fluad Quadrivalent vaccine offers flu protection for adults 65 years old and older. FDA approves Lundbeck’s Vyepti Lundbeck’s Vyepti is the first and only intravenous preventive treatment for migraine. FDA approves Eagle's Pemfexy Eagle has exclusive rights to commercialize Pemfexy for four months beginning Feb. 1, 2022, with an uncapped entry into the market expected on April 1, 2022. Sun Pharma rolls out Absorica LD Sun Pharma's Absorica LD features a special formulation of active ingredient isotretinoin meant to optimize absorption at a 20% lower dose. FDA clears 1st treatment for peanut allergy in children The FDA has approved Palforzia, the first treatment for peanut allergy in children. Fresenius Kabi introduces Glucagon Emergency Kit Fresenius Kabi's glucagon emergency kit provides a treatment for severe hypoglycemia in pediatric and adult patients with diabetes. Seqirus gets FDA nod for Audenz The FDA has approved the first adjuvanted, cell-based Pandemic Influenza A (H5N1) vaccine. Allergan launches Ubrelvy Allergan is offering Ubrelvy for the acute treatment of migraine with or without aura in adults. FDA approves Teva's Ajovy auto-injector device Ajovy offers patients the flexibility of quarterly 675 mg or monthly 225 mg dosing options. First Previous 29 30 31 32 33 Next Last